Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2966577 | 0.95 | HRH3 (0.60) | HRH3TDP1KDM4EALDH1A1CHRNA7 | |
| SCHEMBL2377708 | 0.84 | POLB (0.54) | HRH3TDP1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30917892 | 0.83 | HRH3 (0.60) | HRH3TDP1CHRNA7SMN1; SMN2L3MBTL1 | |
| SCHEMBL20788470 | 0.82 | ALDH1A1 (0.56) | HRH3TDP1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1862135 | 0.82 | HRH3 (0.62) | HRH3TDP1CHRNA7 | |
| SCHEMBL642288 | 0.82 | ALDH1A1 (0.55) | HRH3TDP1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1427022 | 0.82 | ALDH1A1 (0.57) | HRH3TDP1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1861269 | 0.81 | HRH3 (0.72) | HRH3TDP1 | |
| SCHEMBL1872354 | 0.80 | ALDH1A1 (0.59) | HRH3TDP1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2378438 | 0.80 | CYP1A2 (0.50) | HRH3TDP1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321729-B2 | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-26 | — | — | US | disclosed |
| EP-2032536-B1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-06 | — | — | EP | disclosed |
| US-20150087635-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-26 | — | — | US | disclosed |
| US-8940731-B2 | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-27 | — | — | US | disclosed |
| US-20140107105-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (US) | 2014-04-17 | — | — | US | disclosed |
| US-8637520-B2 | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-28 | — | — | US | disclosed |
| US-20100267701-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-21 | — | — | US | disclosed |
| US-7777031-B2 | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-17 | — | — | US | disclosed |
| CN-101495456-A | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-29 | — | — | CN | disclosed |
| EP-2032536-A2 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007143422-A2 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-13 | — | — | WO | disclosed |
| US-20070281923-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087635-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH2 | HRH3 1/4885TDP1 4325/4885KDM4E 748/4885 |
| US-20100267701-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH2 | HRH3 1/4885TDP1 4325/4885KDM4E 748/4885 |
| US-20070281923-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH2 | HRH3 1/4885TDP1 4325/4885KDM4E 748/4885 |
| US-20140107105-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH2 | HRH3 1/4885TDP1 4325/4885KDM4E 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.